{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T08:53:23Z","timestamp":1776934403861,"version":"3.51.2"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.ygyno.2014.06.033","type":"journal-article","created":{"date-parts":[[2014,8,28]],"date-time":"2014-08-28T08:28:58Z","timestamp":1409214538000},"page":"184-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"title":["Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer"],"prefix":"10.1016","volume":"135","author":[{"given":"Daliah","family":"Tsoref","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Welch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susie","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Biagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Tonkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee Ann","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Ellard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prafull","family":"Ghatage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie","family":"Elit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen J.","family":"Mackay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghassan","family":"Allo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Sound","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Kamel-Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Eisenhauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit M.","family":"Oza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2014.06.033_bb0005","author":"Canadian Cancer Society"},{"key":"10.1016\/j.ygyno.2014.06.033_bb0010","series-title":"Handbook of gynaecologic oncology","first-page":"265","author":"Sabbatini","year":"2001"},{"key":"10.1016\/j.ygyno.2014.06.033_bb0015","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1200\/JCO.2004.02.088","article-title":"Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group Study","volume":"22","author":"Thigpen","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.06.033_bb0020","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/annonc\/mdg112","article-title":"Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomized study (55872) by the EORTC Gynecological Cancer Group","volume":"14","author":"Aapro","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2014.06.033_bb0025","first-page":"459","article-title":"Chemotherapy in endometrial cancer","volume":"4","author":"Obel","year":"2006","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.ygyno.2014.06.033_bb0030","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev"},{"key":"10.1016\/j.ygyno.2014.06.033_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4161\/cbt.13.1.18438","article-title":"Personalized therapy in endometrial cancer: challenges and opportunities","volume":"13","author":"Westin","year":"2012","journal-title":"Cancer Biologic Ther"},{"key":"10.1016\/j.ygyno.2014.06.033_bb0040","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1073\/pnas.0806514106","article-title":"Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation","volume":"106","author":"Salvesen","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ygyno.2014.06.033_bb0045","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ygyno.2009.09.038","article-title":"AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma","volume":"116","author":"Cohen","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.06.033_bb0050","doi-asserted-by":"crossref","first-page":"5932","DOI":"10.1158\/1078-0432.CCR-06-1375","article-title":"PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia","volume":"12","author":"Hayes","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.06.033_bb0055","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ygyno.2014.06.033_bb0060","first-page":"789","article-title":"Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells","volume":"2","author":"Zhou","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ygyno.2014.06.033_bb0065","doi-asserted-by":"crossref","first-page":"247.e1-5","DOI":"10.1016\/j.ajog.2006.10.872","article-title":"Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the PTEN heterozygote murine model","volume":"196","author":"Milam","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2014.06.033_bb0070","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1517\/13543784.2014.907272","article-title":"Recent and current phase II clinical trials in endometrial cancer: review of the state of art","volume":"23","author":"Lheureux","year":"2014","journal-title":"Expert Opin Investigating Drugs"},{"key":"10.1016\/j.ygyno.2014.06.033_bb0075","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.5012","article-title":"A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"29","author":"Slomovitz","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.06.033_bb0080","doi-asserted-by":"crossref","first-page":"5516a","DOI":"10.1200\/jco.2007.25.18_suppl.5516","article-title":"A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer","volume":"25S","author":"Colombo","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.06.033_bb0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumours (RECIST guidelines)","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"10.1016\/j.ygyno.2014.06.033_bb0090","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1002\/cncr.25515","article-title":"A Phase II study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma","volume":"116","author":"Slomovitz","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2014.06.033_bb0095","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1200\/JCO.2010.34.1578","article-title":"Phase II study of temsirolimus in women with recurrent or metastastic endometrial cancer: a trial of the NCIC clinical trials group","volume":"29","author":"Oza","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.06.033_bb0100","series-title":"17th AACR_NCI_EORTC International Conference on Molecular Targets and Cancer Therapeutics","first-page":"221a","article-title":"A phase I dose escalation trial of oral AP23573, a novel mTOR inhibitor, in patients with refractory or advanced malignancies","author":"Tolcher","year":"2005"},{"issue":"suppl; abstr 5009","key":"10.1016\/j.ygyno.2014.06.033_bb0105","article-title":"A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotherapy (C) in female adult patients with advanced endometrial carcinoma","volume":"29","author":"Oza","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814010749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814010749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T16:40:09Z","timestamp":1598200809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825814010749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0090825814010749"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.06.033","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718551258.793527270","asserted-by":"object"}]},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.06.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}